National Science Foundation

Remedium Bio is a Boston-based gene therapy company dedicated to developing curative treatments for various debilitating conditions. The company employs a modular approach to research and development, utilizing established technologies in innovative ways to address well-understood disease mechanisms. By focusing on clinically validated molecules and targeted treatment strategies, Remedium Bio aims to create effective therapies for conditions within rheumatology, endocrinology, and neurology. Its pipeline includes promising gene therapy candidates designed to tackle a wide range of diseases, including immune and age-related disorders.

Oculogenex is a biopharmaceutical company that specializes in gene therapy for the treatment of retinal disorders. The company was founded in 2020 and is headquartered in La Habra, California.

Acrigen Biosciences is dedicated to making gene editing safe. It develops technologies to improve efficiency and enhance the safety of CRISPR-Cas based gene editing. CRISPR-Cas system which enables the precise enzymatic editing of genes is one of the most exciting and promising techniques to be developed in the last few years with the capability to prevent or cure many devastating diseases. It was founded in 2019 and is headquartered in Berkeley, California.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Biochip Labs provides blood disorder testing for conditions like sickle cell disease and thalassemia. The company was founded in 2019 and is headquartered in Cleveland, Ohio.

Sequegenics operates a fully automated cloud platform designed to detect structural variants and other complex types of genetic variations. By employing a novel approach that utilizes low-pass long-read next-generation sequencing (NGS), the platform processes raw DNA sequence data efficiently. This innovation allows clients to significantly reduce the time and costs associated with variant calling while enhancing scalability and turnaround times. Sequegenics aims to streamline the detection of complex genetic variations, thereby facilitating more effective genetic analysis for its users.

Kodikaz goal is to move from incremental cancer therapies with devastating side effects to durable cures through targeted therapies that can eradicate cancers. Zip-Code™ Technology platform is a first-in-class, cell-specific delivery system that can be used for a broad range of gene therapy applications. Because the Zip-Codes ™ is derived from an endogenous human mechanism it avoids all of the challenges of viral delivery approaches. The Zip-Codes ™ are universally applicable and specific for each cell type.

Ancilia Biosciences focuses on developing engineered bacterial therapies aimed at treating diseases associated with the microbiome. The company specializes in creating virus-resistant live bacterial products that modulate the human microbiome, specifically targeting the viral components within the gut microbiome. By concentrating on healthy gut bacteria and their predatory phages, Ancilia engineers resistant bacterial strains to combat diseases. Its innovative approach includes the development of a new class of live biotherapeutics that allows medical professionals to target specific phages or viruses that induce lysis, with applications in immunology and oncology.

Tacit Therapeutics created RNA-targeting treatments for devastating diseases. By repurposing pre-existing components of human cells, we have created the first broadly applicable and inherently non-immunogenic means to repair mutated genes. The company was founded in 2021 and is based in South San Francisco, California.

InGateyGen is an agricultural biotechnology company focused on developing and producing hypoallergenic or allergen-reduced peanuts. Utilizing proprietary technologies such as genomics, proteomics, plant tissue culture, and plant propagation, the company aims to create high-value agricultural products that enhance consumer safety and well-being. InGateyGen's commitment to innovation in food science seeks to address the growing demand for allergen-free options, ultimately contributing to improved health outcomes for individuals with peanut allergies.

Oculogenex is a biopharmaceutical company that specializes in gene therapy for the treatment of retinal disorders. The company was founded in 2020 and is headquartered in La Habra, California.

Ansa Biotechnologies is manufactured via a chemical method that has remained essentially unchanged for 35 years and has approached a plateau. Ansa Biotechnologies is developing a novel DNA synthesis technology based on enzymes that will be more fast, accurate, and clean than existing methods. The technique promises to dramatically accelerate innovation in biological research and engineering.

CasTag Biosciences is focused on advancing cell biology and regenerative medicine through innovative tools that enhance the analysis of endogenous proteins. By developing adeno-associated virus kits, the company aims to expedite scientific discovery and empower researchers to investigate novel genes across various experimental models. Utilizing a unique two-vector, clustered regularly interspaced short palindromic repeats-based gene editing technique known as homology-independent universal genome engineering, CasTag's products enable the modification of entire panels of proteins within cells and tissues, thereby facilitating a deeper understanding of biological processes.

Cornerstone Genomics offers advice on the use of genomic tools in human disease and biomedicine, veterinary sciences, and wildlife research. The company was founded in 2017 and is headquartered in Frederick, Maryland.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

Acrigen Biosciences is dedicated to making gene editing safe. It develops technologies to improve efficiency and enhance the safety of CRISPR-Cas based gene editing. CRISPR-Cas system which enables the precise enzymatic editing of genes is one of the most exciting and promising techniques to be developed in the last few years with the capability to prevent or cure many devastating diseases. It was founded in 2019 and is headquartered in Berkeley, California.

Inherent Biosciences is a molecular diagnostics company focused on transforming the trial and error approach in medicine by leveraging insights from epigenetics. The company aims to provide clarity on complex health issues by identifying dysregulation across multiple genes and pathways, which informs personalized treatment strategies. Inherent Biosciences develops innovative therapies for a range of conditions, including pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. By translating biological discoveries into actionable insights, the company seeks to enhance patient care and improve outcomes in various medical fields.

Sumaq Life is a software company that identifies patients who qualify for genomic testing and develops personalized treatment plans based on test results and gene regulatory modeling. Their AI approach allows for both single-agent and multi-agent therapy.

Plastomics Inc. is a biotechnology company specializing in chloroplast genetic engineering to enhance crop performance. Founded in 2016 and based in St. Louis, Missouri, the company focuses on gene stacking and rapid breeding to improve yield production and nutritional quality. Its innovative technology platform allows for the precise insertion of beneficial traits into the chloroplasts of plant cells, facilitating the development of more effective biotech crops. This approach not only addresses current industry challenges but also eliminates cross-pollination, enabling clients to achieve trait expression in plants more reliably. Additionally, Plastomics' unique method of maternal inheritance streamlines breeding timelines and reduces costs, making it a valuable partner for seed companies in the agricultural sector.

A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.

Protabit specializes in protein engineering for various sectors, including industrial, agricultural, and healthcare applications. The company employs a unique platform technology that integrates computational modeling with high-throughput screening and directed evolution to enhance the diversity of protein sequences. This innovative approach allows Protabit to produce novel proteins tailored to specific needs. The development of their technology is supported by strategic partnerships with notable organizations, including Monsanto Company and the California Institute of Technology. Through its advanced methodologies, Protabit aims to advance the field of protein design and provide customized solutions for its clients.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally created at Cornell University, the company specializes in high-efficiency processing of cellular material. Inso Biosciences aims to enhance applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. Their platform facilitates the separation and isolation of cellular components, thereby supporting healthcare and biotech companies in their biological sample preparation needs.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally created at Cornell University, the company specializes in high-efficiency processing of cellular material. Inso Biosciences aims to enhance applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. Their platform facilitates the separation and isolation of cellular components, thereby supporting healthcare and biotech companies in their biological sample preparation needs.

Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for degenerative disorders linked to nucleotide repeat expansions. Founded in 2017 and headquartered in Solana Beach, California, the company is advancing its lead program aimed at treating Friedreich’s ataxia. Additionally, Design Therapeutics is exploring treatments for other conditions such as Fragile X syndrome and myotonic dystrophy, utilizing its proprietary GeneTACTM technology, which involves small-molecule gene-targeted therapeutics designed to modify the underlying causes of these inherited diseases. The company is committed to addressing serious monogenic disorders driven by nucleotide repeat mutations through its ongoing research and development efforts.

Ansa Biotechnologies is manufactured via a chemical method that has remained essentially unchanged for 35 years and has approached a plateau. Ansa Biotechnologies is developing a novel DNA synthesis technology based on enzymes that will be more fast, accurate, and clean than existing methods. The technique promises to dramatically accelerate innovation in biological research and engineering.

Kytopen is a developer of a cell therapy platform that focuses on the non-viral delivery of molecules into challenging immune cells. The company's innovative technology integrates microfluidics and automation to streamline the delivery process, making it faster, easier, and more cost-effective. Kytopen's automated cell engineering platform enables researchers to produce healthy and functional engineered cells rapidly, maintaining their health and functionality. By combining continuous fluid flow with electric fields, Kytopen enhances the efficiency of payload delivery to primary cells, supporting advancements in biology and paving the way for innovative cell and gene therapies.

InGateyGen is an agricultural biotechnology company focused on developing and producing hypoallergenic or allergen-reduced peanuts. Utilizing proprietary technologies such as genomics, proteomics, plant tissue culture, and plant propagation, the company aims to create high-value agricultural products that enhance consumer safety and well-being. InGateyGen's commitment to innovation in food science seeks to address the growing demand for allergen-free options, ultimately contributing to improved health outcomes for individuals with peanut allergies.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Soil Culture Solutions, LLC, founded in 2014 and headquartered in Tampa, Florida, specializes in innovative genetic alteration technology. The company focuses on developing citrus trees that utilize CRISPR editing techniques to enhance resistance to severe diseases affecting the citrus industry. Soil Culture Solutions holds exclusive licenses to patents from community universities, enabling it to employ precision breeding methods to combat these critical infections in citrus crops.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

Rumi Scientific is a research-oriented company focused on developing innovative medications and treatments for genetic disorders affecting the central nervous system, particularly Huntington's Disease. The company utilizes a proprietary human organoid platform that simulates human development in vitro, integrating gene editing techniques with multi-cellular self-organization to create defined diseased embryonic tissues. This advanced platform facilitates drug discovery and high-throughput screening, leveraging artificial intelligence to identify potential treatments. By emphasizing synthetic human embryology in both healthy and diseased contexts, Rumi Scientific aims to advance therapeutic options for numerous genetic conditions that currently lack effective cures. The company's approach combines single-cell, time-lapse imaging with customized analytic tools, resulting in a more efficient and cost-effective drug development process that enhances treatment success rates and outcomes for patients.

Cornerstone Genomics offers advice on the use of genomic tools in human disease and biomedicine, veterinary sciences, and wildlife research. The company was founded in 2017 and is headquartered in Frederick, Maryland.

GenEdit Inc., founded in 2016 and based in Berkeley, California, focuses on advancing gene therapy through its innovative genome editing tools, particularly the CRISPR/Cas9 system. The company aims to address the challenges associated with gene therapy delivery by utilizing its proprietary NanoGalaxy™ platform, which systematically screens a library of nanoparticles to enhance the safety and efficiency of delivering genetic material to target tissues. GenEdit's technology is designed to facilitate therapeutic gene editing, offering a solution that is easier, faster, and more accurate than traditional methods. This positions GenEdit to potentially enable the treatment of previously incurable genetic diseases, significantly contributing to the future of non-viral, gene editing-based therapeutics.

BioInfoExperts specializes in comprehensive molecular surveillance services aimed at understanding infectious disease dynamics and monitoring pathogens. The company offers a range of services, including genomic sequencing, RNA and DNA extraction, data analytics, and cloud-based data visualization. These services are designed to support clients in researching and developing various diagnostic tests while providing essential laboratory capabilities. Through its expertise, BioInfoExperts contributes to advancements in the field of infectious disease management and pathogen tracking.

Parabricks specializes in high-performance genomic analysis software that leverages GPU acceleration and machine learning to enable rapid processing of next-generation sequencing data. The company's technology allows for whole human genome sequencing in under an hour, significantly reducing the time and cost associated with genomic analysis. By providing fast, efficient, and low-cost solutions for genomic data processing, Parabricks enhances the throughput of healthcare facilities, facilitating personalized treatment based on individual genomic variations. This innovative approach has the potential to transform healthcare practices by improving the speed and efficiency of genetic analysis, ultimately leading to better patient outcomes.

Novome Biotechnologies, Inc. is a biotechnology company that focuses on engineering bacteria from the human gut to develop innovative treatments for chronic diseases. Its proprietary platform, which allows for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs), is designed to provide sustained therapeutic effects. Novome's lead preclinical program targets hyperoxaluria by developing a therapeutic strain of bacteria that degrades oxalate, thereby preventing kidney stone formation. The company aims to leverage its synthetic biology tools to expand its applications into additional health conditions, enhancing its ability to deliver precise therapeutic activities through engineered gut microbiota. Founded in 2015, Novome is headquartered in South San Francisco, California.

A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.

Parabricks specializes in high-performance genomic analysis software that leverages GPU acceleration and machine learning to enable rapid processing of next-generation sequencing data. The company's technology allows for whole human genome sequencing in under an hour, significantly reducing the time and cost associated with genomic analysis. By providing fast, efficient, and low-cost solutions for genomic data processing, Parabricks enhances the throughput of healthcare facilities, facilitating personalized treatment based on individual genomic variations. This innovative approach has the potential to transform healthcare practices by improving the speed and efficiency of genetic analysis, ultimately leading to better patient outcomes.

Kytopen is a developer of a cell therapy platform that focuses on the non-viral delivery of molecules into challenging immune cells. The company's innovative technology integrates microfluidics and automation to streamline the delivery process, making it faster, easier, and more cost-effective. Kytopen's automated cell engineering platform enables researchers to produce healthy and functional engineered cells rapidly, maintaining their health and functionality. By combining continuous fluid flow with electric fields, Kytopen enhances the efficiency of payload delivery to primary cells, supporting advancements in biology and paving the way for innovative cell and gene therapies.

Senti Biosciences is a clinical-stage biotechnology company specializing in synthetic biology and gene circuit engineering for therapeutic purposes. The company employs its Gene Circuits platform to develop innovative therapies that enhance precision in targeting cancer cells while avoiding damage to healthy cells. Senti Bio's approach involves the use of allogeneic chimeric antigen receptor natural killer (CAR-NK) cells that incorporate its gene circuit technologies, aimed at addressing various oncology indications. Among its product candidates are SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells without harming healthy bone marrow, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences aims to provide effective treatment options for difficult-to-treat diseases through advanced cell and gene therapies.

Manus Bio Inc. specializes in recreating plant processes within microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company focuses on converting sugar sources into a variety of applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. By integrating metabolic engineering, protein engineering, and systems biology, Manus Bio develops microbes that efficiently manufacture complex and bioactive natural products. The company operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. Formerly known as Manus Biosynthesis, Inc., the company adopted its current name in June 2018.

Yesse Technologies develops a genetic biosensing platform that aims to digitize the sense of smell. The company specializes in biotechnological innovations, utilizing transgenic animals and molecular biology techniques to create super sniffer mice. This unique approach enables the construction of a live, human nose-on-a-chip, which is designed to detect and identify a wide range of odors, from fragrances in perfumery to scents associated with diseases. By merging biological insights with advanced nanotechnology, Yesse Technologies seeks to revolutionize olfaction, allowing users to explore and quantify every smell on the planet.

CrossLife Technologies is a life science firm that creates and sells molecular diagnostics for infectious diseases and non-communicable diseases with the objective of decreasing suffering and enhancing health. They are finding, creating, and commercializing genetic material diagnostic tools.

Inscent is a technology development, gene discovery, and functional genomics company that identified novel molecules to control insect pests. Key areas of interest include the prevention of disease transmission to humans and the development of environmentally friendly products for public health, agricultural, domestic, and industrial applications.

Navipoint Genomics is a bioinformatics analysis software company based in Chicago, Illinois, founded in 2015. The company specializes in developing software that enables the rapid analysis of entire human genomes, facilitating large-scale genomic studies. Its technology streamlines the transfer and examination of genomic data, significantly reducing analysis time while enhancing the ability to detect gene expression changes and fusion transcripts at the whole-transcriptome level. This advanced capability allows clients to achieve higher reporting quality with increased confidence and fewer false negatives in their genomic analyses.

Parabricks specializes in high-performance genomic analysis software that leverages GPU acceleration and machine learning to enable rapid processing of next-generation sequencing data. The company's technology allows for whole human genome sequencing in under an hour, significantly reducing the time and cost associated with genomic analysis. By providing fast, efficient, and low-cost solutions for genomic data processing, Parabricks enhances the throughput of healthcare facilities, facilitating personalized treatment based on individual genomic variations. This innovative approach has the potential to transform healthcare practices by improving the speed and efficiency of genetic analysis, ultimately leading to better patient outcomes.

Varigen Biosciences is developing new technologies for capturing and expressing natural product pathways. Learn about our DNAtrap™ custom cloning service which delivers verified clones of your DNA target (up to 100 kb) in just 10 days at http://varigenbiosciences.com/dnatrap-custom-cloning-service/. Learn about how our BigDNA™ metagenomics libraries can revolutionize natural product discovery at http://varigenbiosciences.com/products/.

enEvolv, Inc. specializes in engineering and licensing microorganisms, including bacteria, yeast, and algae, to produce chemicals, enzymes, and small molecules for various industries such as specialty chemicals, food, energy, personal care, and pharmaceuticals. Founded in 2011 and based in Boston, Massachusetts, enEvolv addresses the growing global demand for essential resources due to population growth and economic development. The company collaborates with other businesses to engineer novel microorganisms and enhance existing strains, aiming to increase production yield and product quality. Utilizing its proprietary genome engineering platform, which employs Multiplex Automated Genome Engineering (MAGE) technology developed at Harvard, enEvolv accelerates the evolution of living cells, offering significant advantages in speed, cost, and engineering capabilities. As of March 2020, enEvolv operates as a subsidiary of Zymergen, Inc.

BioInfoExperts specializes in comprehensive molecular surveillance services aimed at understanding infectious disease dynamics and monitoring pathogens. The company offers a range of services, including genomic sequencing, RNA and DNA extraction, data analytics, and cloud-based data visualization. These services are designed to support clients in researching and developing various diagnostic tests while providing essential laboratory capabilities. Through its expertise, BioInfoExperts contributes to advancements in the field of infectious disease management and pathogen tracking.

Novome Biotechnologies, Inc. is a biotechnology company that focuses on engineering bacteria from the human gut to develop innovative treatments for chronic diseases. Its proprietary platform, which allows for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs), is designed to provide sustained therapeutic effects. Novome's lead preclinical program targets hyperoxaluria by developing a therapeutic strain of bacteria that degrades oxalate, thereby preventing kidney stone formation. The company aims to leverage its synthetic biology tools to expand its applications into additional health conditions, enhancing its ability to deliver precise therapeutic activities through engineered gut microbiota. Founded in 2015, Novome is headquartered in South San Francisco, California.

InGateyGen is an agricultural biotechnology company focused on developing and producing hypoallergenic or allergen-reduced peanuts. Utilizing proprietary technologies such as genomics, proteomics, plant tissue culture, and plant propagation, the company aims to create high-value agricultural products that enhance consumer safety and well-being. InGateyGen's commitment to innovation in food science seeks to address the growing demand for allergen-free options, ultimately contributing to improved health outcomes for individuals with peanut allergies.

Modular Genetics, Inc. is a biotechnology company based in Woburn, Massachusetts, founded in 2000. The company specializes in designing and developing engineered microorganisms that synthesize chemicals from renewable raw materials, primarily sugar. By utilizing a proprietary automated gene engineering system, Modular Genetics enables the rapid development of new products, helping various industries reduce costs and accelerate product innovation. Its focus on sustainable chemistry positions the company as a key player in advancing environmentally friendly manufacturing processes.

T3S Technologies, Inc., established in 2015 and located in Salt Lake City, Utah, specializes in the production of proteins from bacteria. The company utilizes its expertise in genetics and biochemistry, along with proprietary technologies, to genetically engineer bacterial cells. This enables the expression and optimization of challenging recombinant protein products. T3S Technologies' innovations facilitate protein production, which supports researchers in their efforts to develop treatments for chronic diseases.

Mission Bio, Inc. is a biotechnology company that specializes in tools for studying cellular heterogeneity in human health and life sciences. The company has developed the Tapestri Platform, the first single-cell multi-omics platform, which allows for the simultaneous analysis of genotype and phenotype from the same cell. This platform utilizes proprietary microfluidic droplet technology to enable precise detection of genomic variability at single-cell resolution, facilitating research in various applications, including oncology, blood cancers, solid tumors, and genome editing. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating customized single-cell DNA panels, further enhancing its capabilities in targeted molecular analysis. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.

Serotiny, Inc. is a biotechnology company based in San Francisco that specializes in the design and development of multi-domain proteins and therapies for cancer and genetic disorders. Founded in 2014, the company leverages a combination of synthetic biology and advanced informatics to create innovative therapeutic proteins, particularly for CAR T-cell therapies. Its platform integrates computational protein design, high-throughput cellular assays, and next-generation sequencing to engineer complex proteins effectively. By applying expertise from various fields such as immunology, machine learning, and bioinformatics, Serotiny aims to enhance the safety and efficacy of gene and cell therapies through novel control methods and engineered functionalities.

Protabit specializes in protein engineering for various sectors, including industrial, agricultural, and healthcare applications. The company employs a unique platform technology that integrates computational modeling with high-throughput screening and directed evolution to enhance the diversity of protein sequences. This innovative approach allows Protabit to produce novel proteins tailored to specific needs. The development of their technology is supported by strategic partnerships with notable organizations, including Monsanto Company and the California Institute of Technology. Through its advanced methodologies, Protabit aims to advance the field of protein design and provide customized solutions for its clients.

Aperiomics, Inc. is a biotechnology company based in Sterling, Virginia, specializing in pathogen detection services for the animal screening, agricultural testing, and human diagnostics industries. Founded in 2013 and initially known as NextGen Diagnostics, the company changed its name in 2014. Aperiomics utilizes advanced sequencing technologies and a proprietary informatics pipeline to identify a wide range of pathogens, including viral, bacterial, fungal, and parasitic organisms, through a single test. By employing Deep Shotgun Metagenomic Sequencing and leveraging a comprehensive database of over 37,000 microbes, Aperiomics enables medical professionals to identify infections that may be missed by conventional testing methods. This innovative approach has aided many patients suffering from unexplained illnesses by providing accurate diagnoses and facilitating effective treatment pathways. Recognized for its contributions to the field, Aperiomics received accolades such as Life Science Innovator of the Year in 2016 and International Start Up of the Year in 2018.

Knudra Transgenics, LLC is a biotechnology company based in Murray, Utah, specializing in the research, development, and production of DNA mixes and plasmids for the biomedical industry. Founded in 2009, Knudra offers custom transgenics production services, primarily focusing on the model organism Caenorhabditis elegans (C. elegans). The company also provides a cloud-based genome engineering platform that enables biotechnologists to test the genome compositions of various organisms following the injection of external reagents. As a subsidiary of NemaMetrix, Inc., Knudra Transgenics plays a significant role in advancing genetic research and applications in the life sciences sector.

Mission Bio, Inc. is a biotechnology company that specializes in tools for studying cellular heterogeneity in human health and life sciences. The company has developed the Tapestri Platform, the first single-cell multi-omics platform, which allows for the simultaneous analysis of genotype and phenotype from the same cell. This platform utilizes proprietary microfluidic droplet technology to enable precise detection of genomic variability at single-cell resolution, facilitating research in various applications, including oncology, blood cancers, solid tumors, and genome editing. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating customized single-cell DNA panels, further enhancing its capabilities in targeted molecular analysis. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.

Ginkgo Bioworks is a biotechnology company based in Boston, Massachusetts, founded in 2008. It specializes in biological engineering, designing and developing custom microbes and organisms for various applications. The company discovers and licenses molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, it offers probiotic bacteria aimed at protecting against infections and creates libraries of molecules for natural product discovery. Ginkgo Bioworks operates primarily in the markets of cultured ingredients, carbon mitigation, probiotics, and biosecurity. The biosecurity segment, which generates the majority of the company's revenue, provides data analytics and related services to organizations across diverse sectors, including food, agriculture, pharmaceuticals, and specialty chemicals.

TeselaGen Biotechnology is a company that specializes in developing cloud-based tools for DNA design and assembly, aimed at enhancing the efficiency of biological research and development. Founded in 2011 and headquartered in San Francisco, the company offers an informatics platform that integrates artificial intelligence to facilitate the rapid prototyping of recombinant molecules and the synthetic evolution of machine learning engines. Its solutions include a Graphical Sequence Editor for visualizing and editing gene and plasmid libraries, a Symbolic CAD/CAM system for assembling novel constructs from a comprehensive database, and Fabrication Intelligence that generates optimized protocols for cost-effective and accurate DNA assembly. Additionally, TeselaGen provides validation tools to align sequence traces with design variants, thus supporting the large-scale production of DNA assemblies and combinatorial libraries for therapeutics, chemicals, and agricultural applications.

Advirna is a private biotechnology company developing innovative solutions for efficient delivery of polynucleotides in vivo. Advirna’s self-deliverable RNAi is based on the recent breakthrough in biology known as RNA interference (RNAi). This discovery opened a possibility to specifically regulate activity of genes inside a living cell.

Modular Genetics, Inc. is a biotechnology company based in Woburn, Massachusetts, founded in 2000. The company specializes in designing and developing engineered microorganisms that synthesize chemicals from renewable raw materials, primarily sugar. By utilizing a proprietary automated gene engineering system, Modular Genetics enables the rapid development of new products, helping various industries reduce costs and accelerate product innovation. Its focus on sustainable chemistry positions the company as a key player in advancing environmentally friendly manufacturing processes.

Benson Hill is a crop improvement company that unlocks the natural diversity of plants and empowers innovators with a revolutionary crop design platform to develop healthier and more sustainable food and ingredients. Benson Hill empowers innovators to develop more healthy, flavorful, and sustainable food by unlocking the natural genetic diversity of plants. Benson Hill’s CropOS™ platform combines machine learning and big data with breeding techniques and plant biology to drastically accelerate and simplify the product development process.

Protabit specializes in protein engineering for various sectors, including industrial, agricultural, and healthcare applications. The company employs a unique platform technology that integrates computational modeling with high-throughput screening and directed evolution to enhance the diversity of protein sequences. This innovative approach allows Protabit to produce novel proteins tailored to specific needs. The development of their technology is supported by strategic partnerships with notable organizations, including Monsanto Company and the California Institute of Technology. Through its advanced methodologies, Protabit aims to advance the field of protein design and provide customized solutions for its clients.

Molecular Assemblies, Inc. is a San Diego-based company specializing in enzymatic DNA synthesis technology, which facilitates the development of DNA-based products across various industries. Founded in 2013, the company focuses on creating long, high-quality, sequence-specific DNA in a reliable, affordable, and sustainable manner, inspired by natural processes. Its technology has applications in industrial synthetic biology, personalized therapeutics, precision diagnostics, information storage, nanotechnology, and DNA electronics. The firm boasts a skilled executive and scientific team, supported by a robust intellectual property portfolio. Molecular Assemblies has garnered investments from a range of venture capital sources, indicating strong interest in its innovative approach to DNA synthesis.

The J. Craig Venter Institute is a prominent organization in genomic research, established in October 2006 through the merger of several institutions, including The Institute for Genomic Research and The Center for the Advancement of Genomics. With over 400 scientists and staff, the Institute operates from two primary locations in Rockville, Maryland, and San Diego, California, encompassing more than 250,000 square feet of laboratory space. The Institute's research initiatives span a wide range of topics, including genomic medicine, infectious diseases, mammalian genomics, microbial and environmental genomics, and synthetic biology. Notable achievements include the sequencing of the first free-living organism and significant contributions to the human genome project. Recent projects have involved sequencing microbial flora in human environments and discovering millions of new genes from ocean sampling expeditions. The Institute is also actively engaged in creating synthetic organisms and studying the evolution of infectious disease agents, aiming to enhance understanding and treatment of various diseases affecting global health.

Protabit specializes in protein engineering for various sectors, including industrial, agricultural, and healthcare applications. The company employs a unique platform technology that integrates computational modeling with high-throughput screening and directed evolution to enhance the diversity of protein sequences. This innovative approach allows Protabit to produce novel proteins tailored to specific needs. The development of their technology is supported by strategic partnerships with notable organizations, including Monsanto Company and the California Institute of Technology. Through its advanced methodologies, Protabit aims to advance the field of protein design and provide customized solutions for its clients.

Benson Hill is a crop improvement company that unlocks the natural diversity of plants and empowers innovators with a revolutionary crop design platform to develop healthier and more sustainable food and ingredients. Benson Hill empowers innovators to develop more healthy, flavorful, and sustainable food by unlocking the natural genetic diversity of plants. Benson Hill’s CropOS™ platform combines machine learning and big data with breeding techniques and plant biology to drastically accelerate and simplify the product development process.

Inscent is a technology development, gene discovery, and functional genomics company that identified novel molecules to control insect pests. Key areas of interest include the prevention of disease transmission to humans and the development of environmentally friendly products for public health, agricultural, domestic, and industrial applications.

Caribou Biosciences, Inc. is a biotechnology company focused on cellular engineering and genome editing using CRISPR technology. Established in 2011 and based in Berkeley, California, the company leverages its CRISPR-Cas gene editing platform to facilitate precise modifications in DNA across various applications. These include developing therapeutics for human and animal health, creating disease models, enhancing agricultural traits, and advancing industrial biotechnology. Caribou Biosciences is particularly dedicated to the development of genome-edited cell therapies, including allogeneic CAR-T and CAR-NK cell therapies, aimed at improving outcomes for patients with severe diseases. The company’s innovative approach combines CRISPR with guide RNA to enable targeted DNA alterations, thereby contributing to advancements in both therapeutic development and biological research.

Arcadia Biosciences is an agricultural technology company that focuses on developing crop productivity traits, particularly in hemp, wheat, and soybean. The company aims to enhance farm economics by improving crop performance in the field and increasing the value of these crops as food ingredients, health and wellness products, and for industrial applications. Its product offerings include GoodHemp, a range of non-GMO hemp seed varieties, and GoodWheat, which transforms wheat into a functional food to meet consumer demands. Additionally, the company has developed nutritional oils and a drought and herbicide-tolerant soybean trait known as HB4. Arcadia collaborates with various partners, including Ardent Mills and Corteva AgriScience, and operates in multiple regions, including the United States, Canada, Africa, and India. Founded in 2002 and headquartered in Davis, California, Arcadia Biosciences utilizes advanced breeding and biotechnology techniques to create value for consumers, processors, and farmers.

enEvolv, Inc. specializes in engineering and licensing microorganisms, including bacteria, yeast, and algae, to produce chemicals, enzymes, and small molecules for various industries such as specialty chemicals, food, energy, personal care, and pharmaceuticals. Founded in 2011 and based in Boston, Massachusetts, enEvolv addresses the growing global demand for essential resources due to population growth and economic development. The company collaborates with other businesses to engineer novel microorganisms and enhance existing strains, aiming to increase production yield and product quality. Utilizing its proprietary genome engineering platform, which employs Multiplex Automated Genome Engineering (MAGE) technology developed at Harvard, enEvolv accelerates the evolution of living cells, offering significant advantages in speed, cost, and engineering capabilities. As of March 2020, enEvolv operates as a subsidiary of Zymergen, Inc.

Knudra Transgenics, LLC is a biotechnology company based in Murray, Utah, specializing in the research, development, and production of DNA mixes and plasmids for the biomedical industry. Founded in 2009, Knudra offers custom transgenics production services, primarily focusing on the model organism Caenorhabditis elegans (C. elegans). The company also provides a cloud-based genome engineering platform that enables biotechnologists to test the genome compositions of various organisms following the injection of external reagents. As a subsidiary of NemaMetrix, Inc., Knudra Transgenics plays a significant role in advancing genetic research and applications in the life sciences sector.

Manus Bio Inc. specializes in recreating plant processes within microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company focuses on converting sugar sources into a variety of applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. By integrating metabolic engineering, protein engineering, and systems biology, Manus Bio develops microbes that efficiently manufacture complex and bioactive natural products. The company operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. Formerly known as Manus Biosynthesis, Inc., the company adopted its current name in June 2018.

Ginkgo Bioworks is a biotechnology company based in Boston, Massachusetts, founded in 2008. It specializes in biological engineering, designing and developing custom microbes and organisms for various applications. The company discovers and licenses molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, it offers probiotic bacteria aimed at protecting against infections and creates libraries of molecules for natural product discovery. Ginkgo Bioworks operates primarily in the markets of cultured ingredients, carbon mitigation, probiotics, and biosecurity. The biosecurity segment, which generates the majority of the company's revenue, provides data analytics and related services to organizations across diverse sectors, including food, agriculture, pharmaceuticals, and specialty chemicals.

Da Yu Protein Sciences is a research driven biotechnology company developing technologies and services for drug discovery and the bioprocessing industry. Their client base includes biopharmaceutical companies, pharmaceutical companies, and research organizations pursuing drug discovery and development.

Modular Genetics, Inc. is a biotechnology company based in Woburn, Massachusetts, founded in 2000. The company specializes in designing and developing engineered microorganisms that synthesize chemicals from renewable raw materials, primarily sugar. By utilizing a proprietary automated gene engineering system, Modular Genetics enables the rapid development of new products, helping various industries reduce costs and accelerate product innovation. Its focus on sustainable chemistry positions the company as a key player in advancing environmentally friendly manufacturing processes.

Manus Bio Inc. specializes in recreating plant processes within microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company focuses on converting sugar sources into a variety of applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. By integrating metabolic engineering, protein engineering, and systems biology, Manus Bio develops microbes that efficiently manufacture complex and bioactive natural products. The company operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. Formerly known as Manus Biosynthesis, Inc., the company adopted its current name in June 2018.

Ginkgo Bioworks is a biotechnology company based in Boston, Massachusetts, founded in 2008. It specializes in biological engineering, designing and developing custom microbes and organisms for various applications. The company discovers and licenses molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, it offers probiotic bacteria aimed at protecting against infections and creates libraries of molecules for natural product discovery. Ginkgo Bioworks operates primarily in the markets of cultured ingredients, carbon mitigation, probiotics, and biosecurity. The biosecurity segment, which generates the majority of the company's revenue, provides data analytics and related services to organizations across diverse sectors, including food, agriculture, pharmaceuticals, and specialty chemicals.

Akonni Biosystems, Inc. is a biotechnology company based in Frederick, Maryland, specializing in molecular diagnostics. Founded in 2003, the company develops and manufactures integrated diagnostic systems aimed at clinical and life science research markets. Its key product, the TruDiagnosis platform, allows for point-of-care testing of infectious diseases, while TruTip kits assist in DNA and RNA extraction. The company also offers TruArray tests for multiplexed molecular diagnostics, which analyze clinical samples such as blood, saliva, and urine. Akonni's technology is utilized in diagnosing a range of conditions, including infectious diseases, oncology, and genetic disorders. Their innovative systems leverage advanced methods like 3D gel drop microarray technology for effective detection of various health-related targets.

BIORASIS was established in Dec. 2007 with an initial goal to commercialize UCONN’s and OSCI’s wireless, needle-implantable, miniaturized (0.5 x 0.5 x 5 mm) sensor platform for real time, continuous glucose monitoring. In addition to glucose monitoring Biorasis is working towards outfitting its sensor platform to monitor other bio-analytes in the body that are important in other disorders such as cardiovascular, cancer, liver, kidney abnormalities, stroke and epilepsy.

InnoGenomics Technologies specializes in genetic testing solutions, offering a range of services including DNA quantification, short tandem repeat (STR) genotyping, genotyping and gene expression assays, and other DNA-related services. The company has developed a patented technology that is scalable for various applications, such as forensic identification, missing person cases, and establishing familial and ancestral relationships. Additionally, InnoGenomics provides research and development for biological samples, along with validation and training services to support its testing solutions.

TeselaGen Biotechnology is a company that specializes in developing cloud-based tools for DNA design and assembly, aimed at enhancing the efficiency of biological research and development. Founded in 2011 and headquartered in San Francisco, the company offers an informatics platform that integrates artificial intelligence to facilitate the rapid prototyping of recombinant molecules and the synthetic evolution of machine learning engines. Its solutions include a Graphical Sequence Editor for visualizing and editing gene and plasmid libraries, a Symbolic CAD/CAM system for assembling novel constructs from a comprehensive database, and Fabrication Intelligence that generates optimized protocols for cost-effective and accurate DNA assembly. Additionally, TeselaGen provides validation tools to align sequence traces with design variants, thus supporting the large-scale production of DNA assemblies and combinatorial libraries for therapeutics, chemicals, and agricultural applications.

Knudra Transgenics, LLC is a biotechnology company based in Murray, Utah, specializing in the research, development, and production of DNA mixes and plasmids for the biomedical industry. Founded in 2009, Knudra offers custom transgenics production services, primarily focusing on the model organism Caenorhabditis elegans (C. elegans). The company also provides a cloud-based genome engineering platform that enables biotechnologists to test the genome compositions of various organisms following the injection of external reagents. As a subsidiary of NemaMetrix, Inc., Knudra Transgenics plays a significant role in advancing genetic research and applications in the life sciences sector.

Protabit specializes in protein engineering for various sectors, including industrial, agricultural, and healthcare applications. The company employs a unique platform technology that integrates computational modeling with high-throughput screening and directed evolution to enhance the diversity of protein sequences. This innovative approach allows Protabit to produce novel proteins tailored to specific needs. The development of their technology is supported by strategic partnerships with notable organizations, including Monsanto Company and the California Institute of Technology. Through its advanced methodologies, Protabit aims to advance the field of protein design and provide customized solutions for its clients.

MOgene LC, a Limited Liability Company has been in operations since February 2004. The company has established solid reputation as a genomics service provider to academic, government and industrial research groups and institutions. Several papers have been published in leading scientific journals, based on the genomic services provided by MOgene. Company’s management and employees have a vast range of expertise and experience.

Manus Bio Inc. specializes in recreating plant processes within microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company focuses on converting sugar sources into a variety of applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. By integrating metabolic engineering, protein engineering, and systems biology, Manus Bio develops microbes that efficiently manufacture complex and bioactive natural products. The company operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. Formerly known as Manus Biosynthesis, Inc., the company adopted its current name in June 2018.

Divergence is a research and development company focused on creating effective and environmentally sustainable methods for controlling parasites and pests, particularly parasitic nematodes. These roundworms are significant agricultural pests, inflicting billions of dollars in damage to various crops, such as soybeans, corn, cotton, strawberries, and bananas. Additionally, some nematodes are responsible for serious human diseases, including hookworm, whipworm, and roundworm infections, as well as filarial infections that lead to lymphatic filariasis and onchocerciasis. By developing innovative genes and molecules, Divergence aims to address the challenges posed by these harmful organisms in both agricultural and medical contexts.